A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs AMG-301 (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Amgen
- 18 Apr 2019 This trial has been completed in Denmark, according to European Clinical Trials Database.
- 05 Feb 2019 Status changed from active, no longer recruiting to completed.
- 09 Aug 2018 Planned End Date changed from 18 Dec 2018 to 4 Feb 2019.